Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Utility of Circulating Tumor DNA Methylation in the Diagnosis of Primary Lung Cancer

NCT04253509 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT04253509
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04253509 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Utility of Circulating Tumor DNA Methylation in the Diagnosis of Primary Lung Cancer
Lead sponsor
Samsung Medical Center
Phase
Observational
Overall status
Completed
Start date
February 3, 2020
Completion date
January 31, 2022
Enrollment
280 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diagnoses disease, lung cancer